scholarly journals Resveratrol as a Novel Anti-Herpes Simplex Virus Nutraceutical Agent: An Overview

Viruses ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 473 ◽  
Author(s):  
Giuseppe Annunziata ◽  
Maria Maisto ◽  
Connie Schisano ◽  
Roberto Ciampaglia ◽  
Viviana Narciso ◽  
...  

The herpes simplex virus (HSV) is a common human virus affecting many people worldwide. HSV infections manifest with lesions that occur in different parts of the body, including oral, ocular, nasal, and genital skin and mucosa. In rare cases, HSV infections can be serious and lethal. Several anti-HSV drugs have been developed, but the existence of mutant viruses resistant to these drugs led to the individuation of novel antiviral agents. Plant-derived bioactive compounds, and more specifically polyphenols, have been demonstrated to exert marked anti-HSV activity and, among these, resveratrol (RSV) would be considered a good candidate. The purpose of this manuscript is to review the available literature elucidating the efficacy of RSV against HSV and the main demonstrated mechanisms of action.

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 302 ◽  
Author(s):  
Anthony C. Ike ◽  
Chisom J. Onu ◽  
Chukwuebuka M. Ononugbo ◽  
Eleazar E. Reward ◽  
Sophia O. Muo

Herpes simplex virus (HSV) infections are among the most common viral infections and usually last for a lifetime. The virus can potentially be controlled with vaccines since humans are the only known host. However, despite the development and trial of many vaccines, this has not yet been possible. This is normally attributed to the high latency potential of the virus. Numerous immune cells, particularly the natural killer cells and interferon gamma and pathways that are used by the body to fight HSV infections have been identified. On the other hand, the virus has developed different mechanisms, including using different microRNAs to inhibit apoptosis and autophagy to avoid clearance and aid latency induction. Both traditional and new methods of vaccine development, including the use of live attenuated vaccines, replication incompetent vaccines, subunit vaccines and recombinant DNA vaccines are now being employed to develop an effective vaccine against the virus. We conclude that this review has contributed to a better understanding of the interplay between the immune system and the virus, which is necessary for the development of an effective vaccine against HSV.


2014 ◽  
Vol 112 (1) ◽  
pp. E49-E55 ◽  
Author(s):  
Te Du ◽  
Zhiyuan Han ◽  
Guoying Zhou ◽  
Bernard Roizman

The key events in herpes simplex virus (HSV) infections are (i) replication at a portal of entry into the body modeled by infection of cultured cells; (ii) establishment of a latent state characterized by a sole latency-associated transcript and microRNAs (miRNAs) modeled in murine peripheral ganglia 30 d after inoculation; and (iii) reactivation from the latent state modeled by excision and incubation of ganglia in medium containing anti-NGF antibody for a timespan of a single viral replicative cycle. In this report, we examine the pattern of synthesis and accumulation of 18 HSV-1 miRNAs in the three models. We report the following: (i) H2-3P, H3-3P, H4-3P, H5-3P, H6-3P, and H7-5P accumulated in ganglia harboring latent virus. All but H4-3P were readily detected in productively infected cells, and most likely they originate from three transcriptional units. (ii) H8-5P, H15, H17, H18, H26, and H27 accumulated during reactivation. Of this group, only H26 and H27 could be detected in productively infected cells. (iii) Of the 18 we have examined, only 10 miRNAs were found to accumulate above background levels in productively infected cells. The disparity in the accumulation of miRNAs in cell culture and during reactivation may reflect differences in the patterns of regulation of viral gene expression during productive infection and during reactivation from the latent state.


1999 ◽  
Vol 44 (5) ◽  
pp. 705-708 ◽  
Author(s):  
Manuel Cotarelo ◽  
Pilar Catalán ◽  
Carlos Sánchez-Carrillo ◽  
Ana Menasalvas ◽  
Emilia Cercenado ◽  
...  

Author(s):  
Nataliya Nikolaevna Sakhno

Herpetic infection is a disease caused by herpes simplex virus types 1 and 2; it belongs to the category of TORCH infections along with toxoplasmosis, rubella and cytomegalovirus. Herpetic infection is widespread, and recently there has been an increase in the number of cases of herpetic lesions detected, which is most likely due to the expansion of the range of diagnostic tests. Herpes simplex virus type 1 most often affects the skin and mucous membranes, type 2 leads to damage to the urogenital tract. The source of infection can be either a sick person or an asymptomatic carrier. This disease can be transmitted by household contact, during sexual intercourse; the «vertical» route of transmission from mother to child is also known. Depending on the extent of the lesion, localized, widespread and generalized forms are distinguished; the course of herpes infection can be acute, subacute and chronic; latent course of the disease is often found. In addition to the skin and mucous membranes, the central nervous system and (less often) internal organs can be affected. A typical clinical manifestation of herpes simplex is small blistering eruptions that appear on the face, mucous membrane of the lips, wings of the nose, ears, limbs, gluteal folds. The eruptions are usually preceded by itching and hyperemia at the site of the lesion. Diagnosis of herpes infection is carried out on the basis of clinical data and laboratory tests of blood or vesicle contents. Treatment of the disease involves the prescription of antiviral drugs, symptomatic agents, and immunocorrective therapy. Complete removal of the virus from the body is usually impossible, but strengthening the defenses and normalizing the lifestyle contribute to a significant decrease in the frequency of possible relapses.


1995 ◽  
Vol 9 (5) ◽  
pp. 252-255 ◽  
Author(s):  
Edmond Chang ◽  
Noman Absar ◽  
Gildon Beall

Author(s):  
Farah Wasim Aribi Al-Zoobaee ◽  
Loo Yee Shen ◽  
Sajesh K. Veettil ◽  
Divya Gopinath ◽  
Mari Kannan Maharajan ◽  
...  

Cancer therapy may be complicated and compromised by viral infections, including oral herpes simplex virus (HSV) infection. This network meta-analysis aimed to identify the best antiviral agent to prevent or treat oral HSV infection in patients being treated for cancer. A search was conducted for trials published since inception until the 10th of May 2020 in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. A network meta-analysis was performed on the data from randomized controlled trials that assessed antiviral agents for preventive or therapeutic activity vs. placebo, no treatment or any other active intervention in patients being treated for cancer. The agents were ranked according to their effectiveness in the prevention of oral HSV using surface under the cumulative ranking (SUCRA). Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used to assess the certainty of the evidence. In total, 16 articles were included. The pooled relative risk (RR) to develop oral HSV infection in the acyclovir group was 0.17 (95% CI: 0.10, 0.30), compared to 0.22 (95% CI: 0.06, 0.77) in the valacyclovir group. Acyclovir ranked highest for the prevention of oral HSV followed by valacyclovir. Subgroup analysis with different acyclovir regimens revealed that the best regimens in terms of HSV-1 prevention were 750 mg/m2 acyclovir administered intravenously followed by 1600 mg per day orally. Acyclovir (250 mg/m2 per day) administered intravenously was the least effective against the prevention of oral HSV.


Sign in / Sign up

Export Citation Format

Share Document